Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer
Stage-stratified attrition during NAT remains a significant issue even for patients with R disease. The similar OS across stages for resected patients highlights NAT's role in selecting those most likely to benefit from surgery and underscores the need for strategies to reduce attrition.
Authors
- Jashodeep Datta (ORCID: https://orcid.org/0000-0003-2869-1571)
- Dido Franceschi (ORCID: https://orcid.org/0000-0002-2210-069X)
- Gretel Terrero (ORCID: https://orcid.org/0000-0003-1510-2555)
- Nipun B. Merchant (ORCID: https://orcid.org/0000-0002-3399-9776)
- Caitlin A. Hester (ORCID: https://orcid.org/0000-0002-3302-0839)
- Annika Dhawan (ORCID: https://orcid.org/0000-0002-1767-0786)
- Peter J. Hosein (ORCID: https://orcid.org/0000-0001-8537-6397)
- Alan S. Livingstone (ORCID: https://orcid.org/0000-0003-2102-5795)
- Le Min (ORCID: https://orcid.org/0000-0003-4363-1139)
- Erin M. Dickey
- Mary P Martos
Institutions
- University of Miami (US)
- Sylvester Comprehensive Cancer Center (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1245/s10434-025-18664-0
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05